ArticleJournal of cellular and molecular medicine2018
Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma.
Article in Journal of cellular and molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 53 citations in OpenAlex.
- Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer.Hepatology (Baltimore, Md.) · 2019Trial
- Article
- BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy.Journal of ovarian research · 2023Article
- Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer.Journal for immunotherapy of cancer · 2023Article
- A novel T-cell exhaustion-related feature can accurately predict the prognosis of OC patients.Frontiers in pharmacology · 2023Article
- The construction of a prognostic model of cervical cancer based on four immune-related LncRNAs and an exploration of the correlations between the model and oxidative stress.Frontiers in pharmacology · 2023Article
- Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Review
- Review
- Review
- Machine learning analysis of TCGA cancer data.PeerJ. Computer science · 2021Article
- TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.Cancer gene therapy · 2020Review
- Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies.Yonsei medical journal · 2020Article
- Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications.EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.] · 2020Article
- The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers.International journal of molecular sciences · 2020Review
- TIGIT enhances CD4Cancer medicine · 2020Article
- Article
- Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study.Oncoimmunology · 2020Article
- Article
- Tailoring Ovarian Cancer Treatment: Implications ofCancers · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-grade serous ovarian carcinomas (HGSOCs) were among the tumours with an unsatisfactory outcome of immune checkpoint inhibitors (ICIs). It is imperative to develop feasible biomarker for identifying responsive candidates and guiding precise immunotherapy for HGSOC patients. Here, we analysed genomic data of patients with HGSOCs to depict their immunological phenotype of tumour microenvironment (TME) and figure out the major determinants of immunogenicity. In comparison with other solid tumours, we observed the lowest levels of PD-L1, total mutation burden (TMB) and cytolytic molecules in HGSOCs. Surprisingly, TMB is not certainly positively related to tumour immune response as it failed to predict the response to ICIs in a considerable portion of patients in previous clinical trials. By a machine learning approach in search of biomarkers for immunotherapy implications for HGSOCs, we identified the ten most dominant factors determining the immunogenicity of HGSOCs. Interestingly, we found that BRCA1 mutated tumours presented a potent immunogenic phenotype, independent of TMB, meeting the criteria of both our dominant factors and the determinants of immunogenicity established before. Our findings provide evidence that BRCA1-mutation may be served as a predictive biomarker in guiding ICI therapies for the patients with HGSOCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.